This site uses cookies to store information on your computer. Learn more x

DSM Biomedical Expands Portfolio Offering for Ophthalmic Market

Geleen, NL, 30 Apr 2010 13:00 CEST

Next generation biomaterials for controlled drug delivery, contact lens and lens care solutions to be showcased at ARVO.

DSM Biomedical, a global leader in biomedical materials science, and its Berkeley based operation, DSM PTG, will be participating at ARVO 2010 (Booth #813) to provide attendees with an in-depth look at the company’s expanding portfolio of biomedical materials, customized drug delivery systems, contract R&D and manufacturing services for ophthalmic applications. Additionally, the company will be presenting a poster by Ken Messier, Senior Application Development Manager for Drug Delivery, on degradable polyesteramides as a promising platform for delivery of actives to the intra and periocular tissues.

Groundbreaking research, development and manufacturing of specialty polymers and other biomaterials used in a wide range of ophthalmic products has earned DSM Biomedical a successful track record in the fields of pharmaceutical products, devices and consumer goods. Continuing its innovative approach to producing ophthalmic material solutions, the company is actively engaged in developing a diverse product offering including improved materials for use in silicone hydrogel contact lenses and lens care solutions as well as novel sustained release drug delivery systems. Further, the company’s quality system is certified to the ISO 9001 and ISO 13485 standards, providing its partners with an expertise in quality and regulatory compliance.

“DSM Biomedical is committed to providing both novel and cost effective biomaterials that improve the vision, health and comfort of our partners’ ophthalmic patients,” said Bob Ward, CEO and President of DSM PTG. “As a leading, global materials science company, with a wide range of bioresorbable materials for drug delivery, the Trancerta™ drug delivery portfolio as well as advanced biomaterials incorporating Self Assembling Monolayer End Group, SAME ® technology, for contact lens and lens care markets, DSM Biomedical is in a unique position to help our partners bring next-generation ocular therapies to market.”

To learn more about DSM Biomedical’s approach to ophthalmic product development, as well as its biomaterials portfolio, world class R&D and clinical and commercial manufacturing services, please visit Booth #813 at ARVO 2010. Additionally, Ken Messier’s technical poster presentation (Program #5314) will be held on Thursday, May 6 at 8:30 a.m.

Logo